FDA Advisory Committee To Review DOR BioPharma, Inc.'s orBec(R) For The Treatment Of GI GVHD

MIAMI, FL -- (MARKET WIRE) -- January 31, 2007 -- DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or "the Company") announced that it has received notification from the U.S. Food and Drug Administration ("FDA") that the Oncology Drug Advisory Committee ("ODAC") will review the New Drug Application (NDA) for orBec® (oral beclomethasone dipropionate) for the treatment of gastrointestinal Graft-versus-Host disease ("GI GVHD") on May 9, 2007. The FDA has previously said it will respond to DOR's NDA by July 21, 2007 in accordance with the Prescription Drug User Fee Act (PDUFA).